N@N

MDRNA, Inc. to Present at 9th Annual Needham Healthcare Conference

^{Published on 2010-06-02 06:12:26 - Market Wire}
 

BOTHELL, WA--(Marketwire - June 2, 2010) - MDRNA, Inc. (NASDAQ: [ MRNA ]), a leading RNAi-based drug discovery and development company, today announced that it will be presenting at the 9th Annual Needham Healthcare Conference held at the New York Palace Hotel in New York City. J. Michael French, MDRNA's President and Chief Executive Officer, will provide a business update and overview of the Company on Wednesday, June 9, 2010 at 2:40 p.m. (Eastern Time).

To access the live webcast of the MDRNA presentation, please visit the Investors section of the Company's website at [ http://www.mdrnainc.com ] and go to the Event Calendar or click on the following link: [ http://phx.corporate-ir.net/phoenix.zhtml?c=83674&p=irol-irhome ]. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the MDRNA website under Event Calendar approximately one hour after the live presentation and will be archived for three months.

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, amino acid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in oncology. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and liposomal-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at [ http://www.mdrnainc.com ].